Allograft rejection is a complex multicellular process that depends on acquired immunity and requires mature CD4+ T cells, B cells and macrophages. However, activated, previously activated and memory T cells, as well as effector cells, must interact with the graft endothelium in order to mediate rejection. Indeed, increasing evidence supports diverse and important roles for the graft endothelium in alloimmune responses. Vascular Endothelial Growth Factor (VEGF) is an established and most potent angiogenesis factor whose activities include endothelial cell survival, proliferation and migration. In addition, VEGF acts as a proinflammatory cytokine by increasing endothelial cell permeability, inducing the expression of endothelial cell adhesion molecules and via its ability as a monocyte chemoattractant. Furthermore, VEGF has been reported to be expressed in, and to be associated with, acute and chronic allograft rejection. However, no study has evaluated its role or mechanism of action of VEGF in allograft rejection. We hypothesize that VEGF is a proinflammatory cytokine in allografi rejection via its ability to regulate endothelial cell activation responses. Our preliminary studies demonstrate that VEGF augments endothelial cell chemokine production alone and in combination with proinflammatory cytokines. In particular, we have found that VEGF in combination with IFN-gamma synergistically induces the expression of the T cell chemoattractant chemokine IP-10 known to be of functional significance in rejection. We have also found in initial studies that VEGF is functional for the recruitment of alloreactive T cells into allografts. In this research proposal, for the first time we will establish a role for VEGF in alloimmunity. We propose to focus our mechanistic studies on post VEGF receptor signals mediating chemokine production and the effect of VEGF on the NF-kB and STAT family of transcription factors of relevance for the activation of the potent T cell chemoattractant IP-10. Second, we plan to investigate the mechanism of function of VEGF for the recruitment of alloreactive T cells in vitro, and third we will determine if these mechanisms are of importance in allograft rejection in vivo. The results of these studies should yield useful information for the future development of novel therapeutic strategies, and should also provide the foundation for the identification of VEGF as a novel target in allograft rejection.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL074436-04
Application #
7078622
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Massicot-Fisher, Judith
Project Start
2003-08-01
Project End
2008-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
4
Fiscal Year
2006
Total Cost
$395,483
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Singh, Anup Kumar; Arya, Rakesh Kumar; Trivedi, Arun Kumar et al. (2013) Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev 24:41-9
Bruneau, Sarah; Woda, Craig Bryan; Daly, Kevin Patrick et al. (2012) Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation. Front Immunol 3:54
Dormond, Olivier; Dufour, Marc; Seto, Tatsuichiro et al. (2012) Targeting the intragraft microenvironment and the development of chronic allograft rejection. Hum Immunol 73:1261-8
Basu, Aninda; Hoerning, Andre; Datta, Dipak et al. (2010) Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. J Immunol 184:545-9
Edelbauer, Monika; Datta, Dipak; Vos, Ingrid H C et al. (2010) Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo. Blood 116:1980-9
Datta, Dipak; Contreras, Alan G; Basu, Aninda et al. (2009) Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res 69:8902-9
Contreras, Alan G; Briscoe, David M (2007) Every allograft needs a silver lining. J Clin Invest 117:3645-8
Haskova, Zdenka; Izawa, Atsushi; Contreras, Alan G et al. (2007) Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection. Transplantation 83:1595-601
Datta, Dipak; Flaxenburg, Jesse A; Laxmanan, Sreenivas et al. (2006) Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res 66:9509-18
Tsuchihashi, Sei-ichiro; Ke, Bibo; Kaldas, Fady et al. (2006) Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury. Am J Pathol 168:695-705

Showing the most recent 10 out of 13 publications